Trials & Tribulations Why infection and immunity matter for Florida’s cancer patients February 13, 2026Vol.52 No.06By Eduardo Sotomayor
FreeTrials & Tribulations Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore January 30, 2026Vol.52 No.04By Les Biller
Premarin’s 84-year hold on the market ends as FDA approves a generic versionTrade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer January 23, 2026Vol.52 No.03By Claire Marie Porter
News Analysis ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook January 16, 2026Vol.52 No.02By Jacquelyn Cobb and Paul Goldberg
Health Equity New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years January 16, 2026Vol.52 No.02By Sara Willa Ernst
Trials & Tribulations A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers January 16, 2026Vol.52 No.02By Kevin King
A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors? January 09, 2026Vol.52 No.1By Sara Willa Ernst and Jacquelyn Cobb
Trials & Tribulations How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx January 09, 2026Vol.52 No.1By Brendon M. Stiles
Free Oncofertility coverage mandates expand to 21 states and DC as political momentum buildsGaps persist as patients face harrowing decisions and huge copays November 21, 2025Vol.51 No.43By Claire Marie Porter and Sara Willa Ernst
Regulatory News FDA to remove black box warnings on hormone therapy for menopauseTrump-era “gold standard science” is not to be confused with gold standard of scientific evidence November 14, 2025Vol.51 No.42By Claire Marie Porter
